Show simple item record

dc.contributor.authorVillatoro-Villar, M
dc.contributor.authorCrowson, C S
dc.contributor.authorWarrington, K J
dc.contributor.authorMakol, A
dc.contributor.authorKoster, M J
dc.date.accessioned2020-08-10T21:11:20Z
dc.date.available2020-08-10T21:11:20Z
dc.date.issued2020-05-27
dc.identifier.citationM Villatoro-Villar, CS Crowson, KJ Warrington, A Makol & MJ Koster (2020) Immunoglobulin A vasculitis associated with inflammatory bowel disease: a retrospective cohort study, Scandinavian Journal of Rheumatology, DOI: 10.1080/03009742.2020.1732460en_US
dc.identifier.issn0300-9742
dc.identifier.pmid32456601
dc.identifier.doi10.1080/03009742.2020.1732460
dc.identifier.urihttp://hdl.handle.net/10150/642214
dc.description.abstractObjective To describe the baseline characteristics and outcome of a series of patients with inflammatory bowel disease (IBD) and immunoglobulin A vasculitis (IgAV). Method Patients with biopsy-proven IgAV with IBD were identified retrospectively. Data were abstracted from direct medical chart review. Each IBD-IgAV case was matched to two controls with IgAV but without IBD. Results Nine patients were identified (seven Crohn's disease, two ulcerative colitis). Mean length of time between IBD diagnosis and IgAV onset was 17.3 +/- 19.9 years. For patients on biologic treatment for IBD, mean length of time between biologic initiation and IgAV onset was 3.3 +/- 3.8 years. Active IBD at IgAV onset was present in 56%. Tumour necrosis factor inhibitors (TNFi) were used for IBD in 89%. At IgAV onset, six patients were on treatment with TNFi; one subsequently discontinued, two switched to another TNFi, and three continued. At the last follow-up, three of five patients who remained on TNFi had full resolution of IgAV despite ongoing TNFi use. No differences were seen between cases with IBD IgAV and matched non-IBD-IgAV controls regarding development of end-stage renal disease, resolution of haematuria or proteinuria, and time to complete IgAV response. Conclusion Baseline characteristics and outcomes of patients with IBD-IgAV are similar to those with IgAV without IBD. Development of IgAV is not limited to patients with clinically active IBD. Whether TNFi use is related to the pathogenesis of IgAV in some patients with IBD remains unclear. Further research into pathophysiological connections between IBD and IgAV is needed.en_US
dc.language.isoenen_US
dc.publisherTAYLOR & FRANCIS LTDen_US
dc.rightsCopyright © 2020 Informa UK Limited.en_US
dc.rights.urihttp://rightsstatements.org/vocab/InC/1.0/
dc.titleImmunoglobulin A vasculitis associated with inflammatory bowel disease: a retrospective cohort studyen_US
dc.typeArticleen_US
dc.identifier.eissn1502-7732
dc.contributor.departmentUniv Arizona, Div Rheumatol, Arthrit Ctren_US
dc.identifier.journalSCANDINAVIAN JOURNAL OF RHEUMATOLOGYen_US
dc.description.note12 month embargo; published online: 27 May 2020en_US
dc.description.collectioninformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.en_US
dc.eprint.versionFinal accepted manuscripten_US
dc.source.journaltitleScandinavian journal of rheumatology
dc.source.beginpage1
dc.source.endpage8
dc.source.countryEngland


Files in this item

Thumbnail
Name:
Villatoro-Villar_et_al,_IgA_va ...
Size:
353.1Kb
Format:
PDF
Description:
Final Accepted Manuscript

This item appears in the following Collection(s)

Show simple item record